Financial Analysis: Standard BioTools (NASDAQ:LAB) vs. EUDA Health (NASDAQ:EUDA)

EUDA Health (NASDAQ:EUDA) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Earnings & Valuation

This table compares EUDA Health and Standard BioTools”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EUDA Health	$6.82 million	5.43	-$2.77 million	($2.40)	-6.12
Standard BioTools	$85.33 million	4.52	-$74.90 million	$0.20	4.95

EUDA Health has higher earnings, but lower revenue than Standard BioTools. EUDA Health is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for EUDA Health and Standard BioTools, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EUDA Health	1	1	1	0	2.00
Standard BioTools	1	2	0	0	1.67

EUDA Health presently has a consensus target price of $55.00, indicating a potential upside of 274.25%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 36.50%. Given EUDA Health’s stronger consensus rating and higher probable upside, research analysts plainly believe EUDA Health is more favorable than Standard BioTools.

Risk & Volatility

EUDA Health has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

Institutional and Insider Ownership

4.4% of EUDA Health shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 23.2% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares EUDA Health and Standard BioTools’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EUDA Health	N/A	N/A	N/A
Standard BioTools	73.46%	-8.18%	-6.43%

About EUDA Health

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.